WeightWatchers offers Wegovy to clinic members at $299 in July

NEW YORK - WW International, Inc. announced Tuesday an expanded collaboration with Novo Nordisk that will provide WeightWatchers Clinic members access to FDA-approved Wegovy (semaglutide) injection at a reduced price of $299 during July 2025, representing a $200 savings. According to InvestingPro data, WW faces challenging financials with a projected revenue decline of 2% for FY2025 and negative earnings per share forecast, making this partnership potentially crucial for future growth.

The collaboration includes a simplified prescription process through NovoCare Pharmacy, with CenterWell Pharmacy serving as the dispensing pharmacy to facilitate direct fulfillment and home delivery of Wegovy prescriptions for WeightWatchers Clinic members. With a high debt-to-capital ratio of 0.99 and a five-year revenue CAGR of -11%, this strategic partnership could help stabilize WW’s financial position.

"By deepening our collaboration with Novo Nordisk, we are helping more people access the FDA-approved treatment they deserve, delivered within a holistic clinical model proven to support real, sustainable and improved health outcomes," said Scott Honken, Chief Commercial Officer at WeightWatchers.

The companies will also explore opportunities to collaborate on real-world research initiatives to evaluate the potential impact of combining Wegovy with WeightWatchers’ nutrition and behavioral support program.

Dave Moore, Executive Vice President of U.S. Operations at Novo Nordisk Inc., stated, "As we work to expand access to life-changing, FDA-approved treatments like Wegovy, it is essential that we partner with organizations that share our values and focus on improving long-term outcomes."

First approved in 2021, Wegovy is the only FDA-approved semaglutide treatment for weight loss. The FDA expanded its label in 2024 to include an indication for reducing the risk of major cardiovascular events in adults with known heart disease and with either obesity or overweight.

According to a study cited in the press release, WeightWatchers Clinic members prescribed a GLP-1 lost on average 21% of their body weight at 12 months. For detailed analysis of WW’s financial health and growth prospects, including over 30 key financial metrics and expert insights, check out the comprehensive Pro Research Report available exclusively on InvestingPro.

In other recent news, WW International, Inc. is expected to exit its court-supervised financial reorganization process soon, with a plan that significantly reduces its debt by approximately $1.15 billion. The company announced that this will strengthen its capital structure, with lenders receiving new senior secured term loans and common equity. Concurrently, WW International received a notification from Nasdaq regarding the delisting of its common stock, following its Chapter 11 bankruptcy filing. The company plans to list new common equity on a national exchange after emerging from bankruptcy and will trade on the Pink Current Market in the meantime.

Moody’s Ratings has downgraded WW International’s corporate family rating to Ca, reflecting governance concerns and high financial leverage. Similarly, S&P Global Ratings downgraded its issuer credit rating to ’D’ after the bankruptcy filing. Despite these downgrades, the company continues to operate and plans to emerge from bankruptcy within 45 days. In its recent earnings report, WW International posted a Q1 adjusted earnings per share of -$0.47, missing analyst estimates, although revenue surpassed expectations at $186.6 million. The company reported a decline in total subscribers but saw growth in its Clinical subscriber base, which partially offset revenue declines in other areas.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.